title: Role of Immune Therapies for Myeloma.
abstract: Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft- versus-host disease. Recent years have witnessed efforts to induce more selective immune responses via dendritic cell vaccines, autologous and engineered T-cell therapy, and immune checkpoint blockade. Optimizing these immunotherapeutic approaches, understanding how to best use them in combination, and determining how to integrate them with standard anti-myeloma therapy could provide the potential to alter the natural history of this disease.
authors.affiliation: From the Section of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
authors.forename: Jacalyn
authors.initials: J
authors.lastname: Rosenblatt
authors.affiliation: From the Section of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
authors.forename: David
authors.initials: D
authors.lastname: Avigan
mesh_terms: D000818:Animals; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D019496:Cancer Vaccines / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D009101:Multiple Myeloma / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014180:Transplantation / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D060890:B7-H1 Antigen; D019496:Cancer Vaccines; D061026:Programmed Cell Death 1 Receptor; D011948:Receptors, Antigen, T-Cell